Austin Frakt, New York Times contributor and director of the Partnered Evidence-Based Policy Resource Center at the V.A. Boston Healthcare System, examines America’s No. 2 killer among illicit drugs in the United States: cocaine. Frakt shares, “The surge in cocaine deaths has received relatively little attention. The trouble is, there’s a lot less we can do for cocaine than opioids.” This is a pertinent piece that explores the importance of developing effective therapies for the treatment of cocaine use disorder.
The opioid crisis clearly has outpaced all other topics as the story of the year in addiction, and 2018 promises a repeat. Yet with all the justifiable attention to opioid addiction and overdose, is there danger that the next lurking trend in substance use, cocaine and methamphetamine, will emerge as a full-blown epidemic before enough people notice?
Michael Detke, M.D., Ph.D., Embera’s Chief Medical Officer, will moderate the “Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis” panel at 2018 BIO CEO & Investor Conference. The panel will be held on Tuesday, February 13, 2018, at 9 a.m. EST at the New York Marriott Marquis in New York City.
Embera NeuroTherapeutics’s President and Chief Executive Officer, Bob Linke, and Chief Medical Officer, Michael Detke, will present at the 10th Annual Biotech Showcase on Monday, January 8, 2018 at 10:00 a.m. Pacific time.
Embera NeuroTherapeutics, Inc. today announced that Bob Linke, the Company’s President and CEO and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will present at the 2017 BIO Investor Forum on Tuesday, October 17, 2017 at 10:45 a.m. Pacific time.
Embera NeuroTherapeutics, Inc. today announced that Bob Linke, the Company’s President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will provide a corporate update at the 19th Annual Rodman & Renshaw Global Investment Conference.
Researchers and a specialty pharmaceutical company have taken a longstanding theory about addiction and have used it to develop a novel approach to its treatment with medication, in the hope of creating the breakthrough drug for patients with cocaine dependence.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was found to be well-tolerated in a Phase 1b cocaine interaction study, and no new safety signals were observed.
Robert Linke, Embera’s president and CEO, spoke with CEOCFO Magazine regarding Embera’s new approach to treating addictions and how attitudes toward addiction are evolving.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that it has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”